{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:26:03Z","timestamp":1793993163463,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/mp.2015.229","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T09:32:58Z","timestamp":1453800778000},"page":"1527-1536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-4416","authenticated-orcid":false,"given":"I","family":"Loryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Payan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hammarlund-Udenaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,26]]},"reference":[{"key":"BFmp2015229_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s002130050277","volume":"131","author":"S Kapur","year":"1997","unstructured":"Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology 1997; 131: 148\u2013152.","journal-title":"Psychopharmacology"},{"key":"BFmp2015229_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00004714-199802000-00014","volume":"18","author":"G Remington","year":"1998","unstructured":"Remington G, Kapur S, Zipursky R . The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study. J Clin Psychopharmacol 1998; 18: 82\u201383.","journal-title":"J Clin Psychopharmacol"},{"key":"BFmp2015229_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","volume":"157","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C, Remington G, Houle S . Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514\u2013520.","journal-title":"Am J Psychiatry"},{"key":"BFmp2015229_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/clpt.2012.46","volume":"92","author":"T Haslemo","year":"2012","unstructured":"Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M et al. UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. Clin Pharmacol Ther 2012; 92: 221\u2013227.","journal-title":"Clin Pharmacol Ther"},{"key":"BFmp2015229_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/jcbfm.2011.180","volume":"32","author":"E Kim","year":"2012","unstructured":"Kim E, Howes OD, Kim BH, Jeong JM, Lee JS, Jang IJ et al. Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. J Cereb Blood Flow Metab 2012; 32: 759\u2013768.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFmp2015229_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.mp.4001009","volume":"7","author":"J Tauscher","year":"2002","unstructured":"Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S . Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002; 7: 317\u2013321.","journal-title":"Mol Psychiatry"},{"key":"BFmp2015229_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00406-006-0661-7","volume":"256","author":"J Kornhuber","year":"2006","unstructured":"Kornhuber J, Wiltfang J, Riederer P, Bleich S . Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution. Eur Arch Psychiatry Clin Neurosci 2006; 256: 274\u2013280.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFmp2015229_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/00000433-200109000-00014","volume":"22","author":"TC Merrick","year":"2001","unstructured":"Merrick TC, Felo JA, Jenkins AJ . Tissue distribution of olanzapine in a postmortem case. Am J Forensic Med Pathol 2001; 22: 270\u2013274.","journal-title":"Am J Forensic Med Pathol"},{"key":"BFmp2015229_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.forsciint.2005.03.017","volume":"157","author":"KE Rodda","year":"2006","unstructured":"Rodda KE, Dean B, McIntyre IM, Drummer OH . Brain distribution of selected antipsychotics in schizophrenia. Forensic Sci Int 2006; 157: 121\u2013130.","journal-title":"Forensic Sci Int"},{"key":"BFmp2015229_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-2007-979308","volume":"31","author":"M Aravagiri","year":"1998","unstructured":"Aravagiri M, Marder SR, Wirshing D, Wirshing WC . Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998; 31: 102\u2013109.","journal-title":"Pharmacopsychiatry"},{"key":"BFmp2015229_CR11","first-page":"CD006625","volume":"11","author":"L Asmal","year":"2013","unstructured":"Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S . Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013; 11: CD006625.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFmp2015229_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/psp4.38","volume":"4","author":"HS Park","year":"2015","unstructured":"Park HS, Kim E, Moon BS, Lim NH, Lee BC, Kim SE . In vivo tissue pharmacokinetics of carbon-11-labeled clozapine in healthy volunteers: a positron emission tomography study. CPT Pharmacometrics Syst Pharmacol 2015; 4: 305\u2013311.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"BFmp2015229_CR13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","volume":"25","author":"M Hammarlund-Udenaes","year":"2008","unstructured":"Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A . On the rate and extent of drug delivery to the brain. Pharmaceut Res 2008; 25: 1737\u20131750.","journal-title":"Pharmaceut Res"},{"key":"BFmp2015229_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2045-8118-10-6","volume":"10","author":"I Loryan","year":"2013","unstructured":"Loryan I, Friden M, Hammarlund-Udenaes M . The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS 2013; 10: 6.","journal-title":"Fluids Barriers CNS"},{"key":"BFmp2015229_CR15","first-page":"271","volume-title":"Drug Delivery to the Brain","author":"Irena Loryan","year":"2013","unstructured":"Loryan I, Hammarlund-Udenaes M. Drug discovery methods for studying brain drug delivery and distribution. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG (eds). Drug Delivery to the Brain. Springer: New York, USA, 2014, pp 271\u2013316."},{"key":"BFmp2015229_CR16","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1124\/dmd.107.015222","volume":"35","author":"M Friden","year":"2007","unstructured":"Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M . In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 2007; 35: 1711\u20131719.","journal-title":"Drug Metab Dispos"},{"key":"BFmp2015229_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/ALN.0b013e318164cf9e","volume":"108","author":"E Bostrom","year":"2008","unstructured":"Bostrom E, Hammarlund-Udenaes M, Simonsson US . Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 2008; 108: 495\u2013505.","journal-title":"Anesthesiology"},{"key":"BFmp2015229_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.107.119560","volume":"323","author":"JC Kalvass","year":"2007","unstructured":"Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM . Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 2007; 323: 346\u2013355.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFmp2015229_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1124\/dmd.108.022814","volume":"37","author":"J Watson","year":"2009","unstructured":"Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S et al. Receptor occupancy and brain free fraction. Drug Metab Dispos 2009; 37: 753\u2013760.","journal-title":"Drug Metab Dispos"},{"key":"BFmp2015229_CR20","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1124\/dmd.109.026674","volume":"37","author":"X Liu","year":"2009","unstructured":"Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R . Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 2009; 37: 1548\u20131556.","journal-title":"Drug Metab Dispos"},{"key":"BFmp2015229_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1124\/dmd.104.001222","volume":"33","author":"TS Maurer","year":"2005","unstructured":"Maurer TS, Debartolo DB, Tess DA, Scott DO . Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005; 33: 175\u2013181.","journal-title":"Drug Metab Dispos"},{"key":"BFmp2015229_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/0024-3205(92)90413-J","volume":"51","author":"M Ekblom","year":"1992","unstructured":"Ekblom M, Gardmark M, Hammarlund-Udenaes M . Estimation of unbound concentrations of morphine from microdialysate concentrations by use of nonlinear regression analysis in vivo and in vitro during steady state conditions. Life Sci 1992; 51: 449\u2013460.","journal-title":"Life Sci"},{"key":"BFmp2015229_CR23","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1023\/A:1026414713509","volume":"17","author":"MR Bouw","year":"2000","unstructured":"Bouw MR, Gardmark M, Hammarlund-Udenaes M . Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats\u2014a microdialysis study. Pharmaceut Res 2000; 17: 1220\u20131227.","journal-title":"Pharmaceut Res"},{"key":"BFmp2015229_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1742-7843.2009.00517.x","volume":"106","author":"M Hammarlund-Udenaes","year":"2010","unstructured":"Hammarlund-Udenaes M . Active-site concentrations of chemicals - are they a better predictor of effect than plasma\/organ\/tissue concentrations? Basic Clin Pharmacol Toxicol 2010; 106: 215\u2013220.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"BFmp2015229_CR25","first-page":"127","volume-title":"Drug Delivery to the Brain","author":"Margareta Hammarlund-Udenaes","year":"2013","unstructured":"Hammarlund-Udenaes M. Pharmacokinetic concepts in brain drug delivery. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG (eds). Drug Delivery to the Brain. Springer: New York, USA, 2014, pp 127\u2013161.."},{"key":"BFmp2015229_CR26","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","volume":"56","author":"DD Shen","year":"2004","unstructured":"Shen DD, Artru AA, Adkison KK . Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004; 56: 1825\u20131857.","journal-title":"Adv Drug Deliv Rev"},{"key":"BFmp2015229_CR27","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1021\/jm901036q","volume":"52","author":"M Friden","year":"2009","unstructured":"Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 2009; 52: 6233\u20136243.","journal-title":"J Med Chem"},{"key":"BFmp2015229_CR28","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s11095-014-1319-1","volume":"31","author":"I Loryan","year":"2014","unstructured":"Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg W, Vermeulen A et al. Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery. Pharmaceut Res 2014 2014\/08\/01 31: 2203\u20132219.","journal-title":"Pharmaceut Res"},{"key":"BFmp2015229_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1471-4159.1966.tb09873.x","volume":"13","author":"J Glowinski","year":"1966","unstructured":"Glowinski J, Iversen LL . Regional studies of catecholamines in the rat brain-I. J Neurochem 1966; 13: 655\u2013669.","journal-title":"J Neurochem"},{"key":"BFmp2015229_CR30","doi-asserted-by":"crossref","unstructured":"Chiu K, Lau WM, Lau HT, So K-F, Chang RC-C . Micro-dissection of rat brain for RNA or protein extraction from specific brain region. J Vis Exp 2007; 269.","DOI":"10.3791\/269"},{"key":"BFmp2015229_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/bdd.325","volume":"23","author":"JC Kalvass","year":"2002","unstructured":"Kalvass JC, Maurer TS . Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002; 23: 327\u2013338.","journal-title":"Biopharm Drug Dispos"},{"key":"BFmp2015229_CR32","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1124\/dmd.108.026377","volume":"37","author":"M Friden","year":"2009","unstructured":"Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M . Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 2009; 37: 1226\u20131233.","journal-title":"Drug Metab Dispos"},{"key":"BFmp2015229_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1113\/jphysiol.1910.sp001377","volume":"40","author":"AV Hill","year":"1910","unstructured":"Hill AV . The heat produced in contracture and muscular tone. J Physiol 1910; 40: 389\u2013403.","journal-title":"J Physiol"},{"key":"BFmp2015229_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57\u201373.","journal-title":"Psychopharmacology"},{"key":"BFmp2015229_CR35","volume-title":"Prism 5 Statistics Guide","author":"HJ Motulsky","year":"2007","unstructured":"Motulsky HJ (ed). Prism 5 Statistics Guide. GraphPad Software Inc.: San Diego, CA, USA, 2007."},{"key":"BFmp2015229_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/jcbfm.2009.200","volume":"30","author":"M Friden","year":"2010","unstructured":"Friden M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M . Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab 2010; 30: 150\u2013161.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFmp2015229_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/2191-219X-2-58","volume":"2","author":"J Mullauer","year":"2012","unstructured":"Mullauer J, Kuntner C, Bauer M, Bankstahl JP, Muller M, Voskuyl RA et al. Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Res 2012; 2: 58.","journal-title":"EJNMMI Res"},{"key":"BFmp2015229_CR38","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s00259-009-1332-5","volume":"37","author":"C Kuntner","year":"2010","unstructured":"Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging 2010; 37: 942\u2013953.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFmp2015229_CR39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/jcbfm.2009.265","volume":"30","author":"M Bauer","year":"2010","unstructured":"Bauer M, Karch R, Neumann F, Wagner CC, Kletter K, Muller M et al. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab 2010; 30: 510\u2013515.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFmp2015229_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ana.22421","volume":"70","author":"V Bartanusz","year":"2011","unstructured":"Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M . The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011; 70: 194\u2013206.","journal-title":"Ann Neurol"},{"key":"BFmp2015229_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/2045-8118-11-25","volume":"11","author":"X Chen","year":"2014","unstructured":"Chen X, Loryan I, Payan M, Keep RF, Smith DE, Hammarlund-Udenaes M . Effect of transporter inhibition on the distribution of cefadroxil in rat brain. Fluids Barriers CNS 2014; 11: 25.","journal-title":"Fluids Barriers CNS"},{"key":"BFmp2015229_CR42","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1124\/dmd.110.035998","volume":"39","author":"M Friden","year":"2011","unstructured":"Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 2011; 39: 353\u2013362.","journal-title":"Drug Metab Dispos"},{"key":"BFmp2015229_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/jps.20792","volume":"96","author":"AM Kaufmann","year":"2007","unstructured":"Kaufmann AM, Krise JP . Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 2007; 96: 729\u2013746.","journal-title":"J Pharm Sci"},{"key":"BFmp2015229_CR44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/sj.bjp.0704319","volume":"134","author":"WA Daniel","year":"2001","unstructured":"Daniel WA, Wojcikowski J, Palucha A . Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. Br J Pharmacol 2001; 134: 807\u2013814.","journal-title":"Br J Pharmacol"},{"key":"BFmp2015229_CR45","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s11095-014-1319-1","volume":"13","author":"I Loryan","year":"2014","unstructured":"Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg W, Vermeulen A et al. Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery. Pharmaceut Res 2014; 13: 2203\u20132219.","journal-title":"Pharmaceut Res"},{"key":"BFmp2015229_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/mp5005965","volume":"12","author":"I Loryan","year":"2014","unstructured":"Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg WH, Vermeulen A et al. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. Mol Pharmaceut 2014; 12: 520\u2013532.","journal-title":"Mol Pharmaceut"},{"key":"BFmp2015229_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-1781(88)90029-7","volume":"23","author":"CN Svendsen","year":"1988","unstructured":"Svendsen CN, Hrbek CC, Casendino M, Nichols RD, Bird ED . Concentration and distribution of thioridazine and metabolites in schizophrenic post-mortem brain tissue. Psychiatry Res 1988; 23: 1\u201310.","journal-title":"Psychiatry Res"},{"key":"BFmp2015229_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1155\/2009\/278531","volume":"2009","author":"H Shalev","year":"2009","unstructured":"Shalev H, Serlin Y, Friedman A . Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol 2009; 2009: 7.","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"BFmp2015229_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pscychresns.2010.05.002","volume":"183","author":"OL de Klerk","year":"2010","unstructured":"de Klerk OL, Willemsen AT, Bosker FJ, Bartels AL, Hendrikse NH, den Boer JA et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res 2010; 183: 151\u2013156.","journal-title":"Psychiatry Res"},{"key":"BFmp2015229_CR50","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0304-3940(98)00655-7","volume":"253","author":"MJ Schwarz","year":"1998","unstructured":"Schwarz MJ, Ackenheil M, Riedel M, Muller N . Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 1998; 253: 201\u2013203.","journal-title":"Neurosci Lett"},{"key":"BFmp2015229_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.psychres.2014.03.045","volume":"217","author":"H Zetterberg","year":"2014","unstructured":"Zetterberg H, Jakobsson J, Redsater M, Andreasson U, Palsson E, Ekman CJ et al. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res 2014; 217: 143\u2013146.","journal-title":"Psychiatry Res"},{"key":"BFmp2015229_CR52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/bjp.bp.107.037218","volume":"192","author":"S Lewis","year":"2008","unstructured":"Lewis S, Lieberman J . CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 2008; 192: 161\u2013163.","journal-title":"Br J Psychiatry"},{"key":"BFmp2015229_CR53","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951\u2013962.","journal-title":"Lancet"},{"key":"BFmp2015229_CR54","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1124\/jpet.102.035303","volume":"302","author":"S Kapur","year":"2002","unstructured":"Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS . The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002; 302: 1129\u20131134.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFmp2015229_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/bs.apha.2014.06.010","volume":"71","author":"T Ashraf","year":"2014","unstructured":"Ashraf T, Kao A, Bendayan R . Functional expression of drug transporters in glial cells: potential role on drug delivery to the CNS. Adv Pharmacol 2014; 71: 45\u2013111.","journal-title":"Adv Pharmacol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/mp2015229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp2015229","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp2015229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:34:57Z","timestamp":1648780497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp2015229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,26]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFmp2015229"],"URL":"https:\/\/doi.org\/10.1038\/mp.2015.229","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,26]]},"assertion":[{"value":"19 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}